Fenofibrate Tablets USP, 48 mg and 145 mg have an estimated market size of US$ 94 mn for twelve months ending December 2018, according to IQVIA.
Alembic now has a total of 102 ANDA approvals (90 final approvals and 12 tentative approvals) from USFDA.
Fenofibrate Tablets, USP are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL- C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia.
It is also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g.> 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied.
Alembic Pharmaceuticals Ltd is currently trading at Rs541, down by Rs4.35 or 0.8% from its previous closing of Rs545.35 on the BSE.
The scrip opened at Rs545.50 and has touched a high and low of Rs545.50 and Rs533.50 respectively.